Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in
Qin Zhang1,2, Liansha Tang3, Yuwen Zhou3
1Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.
Checkpoint inhibitor pneumonitis (CIP) is a serious immune-related adverse event in non-small cell lung cancer (NSCLC) patients treated with immunotherapy. This review summarizes CIP characteristics, diagnosis, and management, focusing on optimal steroid use in NSCLC.
Area of Science:
- Oncology
- Immunology
- Pulmonology
Background:
- Immunotherapy targeting PD-1, PD-L1, and CTLA-4 has transformed cancer treatment.
- Immune-related adverse events (irAEs), including checkpoint inhibitor pneumonitis (CIP), are common.
- CIP is a particularly concerning irAE, especially in non-small cell lung cancer (NSCLC) patients due to overlapping symptoms.
Purpose of the Study:
- To comprehensively review the characteristics, diagnosis, and management of CIP.
- To discuss the optimal steroid therapeutic schedule for NSCLC patients with CIP.
Main Methods:
- Systematic review of relevant literature on CIP in cancer patients.
- Analysis of diagnostic criteria and management strategies for CIP.
- Evaluation of current evidence regarding steroid therapy for CIP in NSCLC.
Main Results:
- CIP presents unique challenges in NSCLC patients due to potential symptom overlap with the primary tumor.
- Early recognition and appropriate management are crucial for favorable outcomes in CIP.
- Steroid therapy remains a cornerstone of CIP management, with ongoing research into optimal protocols.
Conclusions:
- CIP is a significant irAE in NSCLC patients receiving immunotherapy, requiring careful monitoring and management.
- A thorough understanding of CIP's characteristics and diagnostic approaches is essential.
- Further research is needed to define optimal steroid regimens for managing CIP in NSCLC.
More Related Videos
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
